Challenges for Clinical Trials to Treat Progressive Multifocal Leukoencephalopathy

References

• Antinori A, A=assari A, Cinque P, Toma L, Govoni A, Soldani F, Giancola ML, Grisetti S, Pierotti C, Fausti C, Finazzi MG, Bini T, Del Grosso B, Cristiano L, Corsi P, Fa-sub o G, Mena M, Guaraldi G, Arcidiacono MI, Monno L, Gigli B, Fibbia GC, Gentile M, Mastroianni A, Speranza F, d'Arminio Monforte A, Rezza G, Ippolito G (2001). Shift of prevalence and selected characteristics in HIV-1-related neurologic disorders in HAART era: data from Italian Register Investigative Neuro AIDS (IRINA). Pre-sented at the 8th Conference on Retroviruses and Op-portunistic Infections, Chicago, Feb 4–8.
   Google Scholar
• Atwood WJ (2001). A combination of low-dose chlorpro-mazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implica-tions for prophylactic and therapeutic treatment of pro-gressive multifocal leukencephalopathy. J NeuroVirol 7: 307–310.
   PubMed Web of Science ®Google Scholar
• Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998). Predic-tive factors for prolonged survival in acquired immun-odeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44: 341–349.
   Google Scholar
• Cinque P, Casari S, Bertelli D (1998). Progressive multifocal leukoencephalopathy, HIV and highly active antiretro-viral therapy. N Engl j Med 339: 848–849.
   Google Scholar
• Clifford DB, Neurological AIDS Research Consortium Study Team (1998). Impact on highly active antiretro-viral therapy on survival from progressive multifo-cal leukoencephalopathy in human immunodeficiency virus infection. Neurology 50: A249.
   Google Scholar
• Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999). HAART im-proves prognosis in HIV-associated progressive multifo-cal leukoencephalopathy. Neurology 52: 623–625.
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Wan PT, Hanson DL, Jones JL, Adult & Adolescent Spectrum of HIV Disease Project (1999). Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected pa-tients in the protease inhibitor era. /Infect Dis 180: 621–625.
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Skolasky RI, Royal WS, McArthur JC (2001). The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoen-cephalopathy in AIDS. J NeuroVirol 7: 353–357.
   PubMed Web of Science ®Google Scholar
• Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Liike W, Lazzarin A, Weber T, Cinque P (2000). Highly active antiretroviral therapy and progressive multifo-cal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30: 95–99.
   PubMed Web of Science ®Google Scholar
• Hall CD, Dafni U, Simpson D, Clifford DB, Wetherill PE, Cohen B, McArthur JC, Hollander H, Yiannoutsos C, Ma-jor E, Millar L, Timpone J, AIDS Clinical Trials Group 243 Team (1998). Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 338: 1345–1351.
   PubMed Web of Science ®Google Scholar
• Hou J, Major EO (1998). The efficacy of nucleoside analogs against JC virus multiplication in a persistently in-fected human fetal brain cell line. J NeuroVirol 4: 451–456.
   PubMed Web of Science ®Google Scholar
• Inui K, Miyagawa H, Sashihara J, Miyoshi H, Tanaka-Taya K, Nishigaki T, Teraoka S, Mano T, Ono J, Okada S (1999). Remission of progressive multifocal leukoencephalopa-thy following highly active antiretroviral therapy in a patient with HIV infection. Brain Dev 21: 416–419.
   PubMedGoogle Scholar
• Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T, Masliah E, HNRC Group (2002). Severe, demyelinating leukoencepahlopathy in AIDS patients on antiretroviral therapy. AIDS 16: 1019–1029.
   PubMed Web of Science ®Google Scholar
• Levy RM, Major E, Ali MJ, Cohen B, Groothius D (2001). Convection-enhanced intraparenchymal deliv-ery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoen-cephalopathy (PML). J NeuroVirol 7: 382–385.
   Google Scholar
• Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Post MJD, Ruiz A, Bowen BC, Huang ML, Queen-Baker J, Andersen J, Kelly S, Shriver S, ACTG 363 Team (2002). A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16: 1–7.
   Google Scholar
• Pho MT, Ashok A, Atwood WJ (2000). JC virus enters hu-man glial cells by clathrin- dependent receptor-mediated endocytosis. J Virol 74: 2288–2292.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Aksamit AJ, Wright AJ, Wilson JW (2001). Cidofovir treatment of progressive multifo-cal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin Proc 76: 1171–1175.
   PubMed Web of Science ®Google Scholar
• Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ (1999). Progressive multifocal leukoen-cephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28: 1152–1154.
   PubMedGoogle Scholar
• Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boué F, Billaud E, Costagliola D, Clinical Epidemiology Group from the French Hospital Database on HIV (1999). Sur-vival improvement of AIDS-related progressive multi-focal leukoencephalopathy in the era of protease in-hibitors. AIDS 13: 1881–1887.
   PubMed Web of Science ®Google Scholar